Is BCDAW or ORCC a better dividend investment in 2026?

BCDAW currently yields 32786.89% with a 5% 5-year dividend growth rate. ORCC yields 9.79% with 5% growth. The better choice depends on your goal: BCDAW offers higher current income.

What is the dividend yield difference between BCDAW and ORCC?

BCDAW has a forward dividend yield of 32786.89% ($2.00/share annually). ORCC yields 9.79% ($1.32/share annually). The yield gap is 32777.10 percentage points.

Home › Compare › BCDAW vs ORCC

BCDAW vs ORCC: Dividend Comparison 2026

BCDAW yields 32786.89% · ORCC yields 9.79%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 BCDAW wins by $7.149378406802545e+21M in total portfolio value

INVESTMENT

TIME HORIZON10 years

BCDAW

● Live price

32786.89%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$7.149378406802545e+21M

Annual income

$7,106,739,309,572,423,000,000,000,000.00

Full BCDAW calculator →

ORCC

● Live price

9.79%

Share price

$13.48

Annual div

$1.32

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$21.4K

Annual income

$1.04

Full ORCC calculator →

Portfolio growth — BCDAW vs ORCC

📍 BCDAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BCDAW	ORCC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BCDAW + ORCC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BCDAW pays

ORCC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCDAW

Annual income on $10K today (after 15% tax)

$2,786,885.25/yr

After 10yr DRIP, annual income (after tax)

$6,040,728,413,136,559,000,000,000,000.00/yr

ORCC

Annual income on $10K today (after 15% tax)

$832.34/yr

After 10yr DRIP, annual income (after tax)

$0.88/yr

At 15% tax rate, BCDAW beats the other by $6,040,728,413,136,559,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCDAW + ORCC for your $10,000?

BCDAW: 50%ORCC: 50%

100% ORCC50/50100% BCDAW

Portfolio after 10yr

$3.5746892034012726e+21M

Annual income

$3,553,369,654,786,211,600,000,000,000.00/yr

Blended yield

99.40%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

BCDAW

No analyst data

Altman Z

-75.0

Piotroski

2/9

ORCC

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$16.00

+18.7% upside vs current

Range: $16.00 — $16.00

Altman Z

0.5

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCDAW buys

ORCC buys

Politician	Chamber	Ticker	Type	Amount	Date
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-23
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$250,001 - $500,000	2022-06-16
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-14
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$50,001 - $100,000	2022-06-13
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$50,001 - $100,000	2022-06-10
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-09
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-08
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$50,001 - $100,000	2022-06-03
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-05-24
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$100,001 - $250,000	2022-05-20

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBCDAWORCC

Forward yield	32786.89% ✓	9.79%
Annual dividend / share	$2.00 ✓	$1.32
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0% ✓	-50%
Portfolio after 10y	$7.149378406802545e+21M	$21.4K ✓
Annual income after 10y	$7,106,739,309,572,423,000,000,000,000.00 ✓	$1.04
Total dividends collected	$7.146574325368343e+21M ✓	$1.0K
Payment frequency	quarterly	quarterly
Sector	Stock	BDC

Year-by-year: BCDAW vs ORCC ($10,000, DRIP)

Year	BCDAW Portfolio	BCDAW Income/yr	ORCC Portfolio	ORCC Income/yr	Gap
1← crossover	$3,289,389	$3,278,688.52	$11,190	$489.61	+$3.28M → BCDAW
2	$1,011,452,394	$1,007,932,748.46	$12,229	$256.01	+$1011.44M → BCDAW
3	$290,735,268,121	$289,653,014,059.08	$13,216	$130.74	+$290735.25M → BCDAW
4	$78,123,080,869,461	$77,811,994,132,571.95	$14,207	$66.02	+$78123080.86M → BCDAW
5	$19,624,484,924,633,140	$19,540,893,228,102,816.00	$15,234	$33.17	+$19624484924.62M → BCDAW
6	$4,608,534,766,328,053,000	$4,587,536,567,458,695,700.00	$16,317	$16.62	+$4608534766328.04M → BCDAW
7	$1,011,770,904,242,838,300,000	$1,006,839,772,042,867,400,000.00	$17,468	$8.32	+$1011770904242838.25M → BCDAW
8	$207,666,224,199,856,750,000,000	$206,583,629,332,316,930,000,000.00	$18,695	$4.16	+$207666224199856768.00M → BCDAW
9	$39,849,623,579,553,230,000,000,000	$39,627,420,719,659,375,000,000,000.00	$20,006	$2.08	+$39849623579553226752.00M → BCDAW
10	$7,149,378,406,802,546,000,000,000,000	$7,106,739,309,572,423,000,000,000,000.00	$21,407	$1.04	+$7.149378406802545e+21M → BCDAW

BCDAW vs ORCC: Complete Analysis 2026

BCDAW — Stock

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Full BCDAW Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →

📬

Get this BCDAW vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCDAW vs SCHD BCDAW vs JEPI BCDAW vs O BCDAW vs KO BCDAW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.